Celyad will soon begin clinical development of its immunotherapy CYAD-101 (CAR-T NKG2D) and evaluate its potential as a treatment for patients with colorectal cancer that cannot be surgically removed. The first-in-human Phase 1 trial, called Allo-SHRINK … (본문 전체 8/2/2018 12:59 AM)